DSE:CENTRALPHL

Central Pharmaceuticals Ltd. research

Reports on Central Pharmaceuticals Ltd.

Company · Analysis · 31 Oct 2026

Central Pharmaceuticals: adverse audit opinion on FY2025, turnover of BDT 33.1m and sponsors at 7.67%

A Z-category DSE drug maker with one factory in Mirpur, Dhaka: seven years of filings, an auditor's adverse opinion on the FY2025 accounts, BDT 268.5m of Janata Bank loans carried without change since before June 2022, and FY2026 results announced on 27-Oct-2026.

MISSING FILING and data status. Central Pharmaceuticals Ltd. (CPL) has a 30 June year end. The latest annual report in the corpus covers the year to 30-Jun-2025: the statement of financial position is headed 'AS AT 30 JUNE 2025' and the auditor signed on November…

Peer comparisons and industry research covering Central Pharmaceuticals Ltd.

Company · DSE:AMBEEPHA · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026

Ambee Pharmaceuticals: FY2025 revenue of BDT 230.6m, BDT 661.1m of 'liabilities for other finance' on BDT 32.3m of equity, and a qualified audit opinion

A 1976-incorporated Tejgaon drug maker selling tablets, capsules, liquids, ointments and ampoules: five years of filings, 9M FY2026 revenue down 40.9% on 9M FY2025, a BDT 52.6m share investment first recorded in FY2025, and FY2026 accounts not yet in the corpus at 2-Nov-2026.

Ambee Pharmaceuticals PLC was incorporated in Bangladesh as a public company on 4 February 1976, began commercial operation in 1978 and issued shares to the public in 1986; its shares are listed on the Dhaka and Chittagong stock exchanges. The registered office and the manufacturing…

All Bangladesh research →